

Seraseq® gDNA and FFPE TMB Products

HUMAN CELL LINE-DERIVED REFERENCE SAMPLES, TUMOR-NORMAL MATCHED SET, WITH RANGE OF TMB SCORES FOR VALIDATION AND USE OF TARGETED NGS PANEL IN TMB MEASUREMENTS.

HIGHLIGHTS

DERIVED FROM HUMAN LUNG CANCER CELL LINES AND MATCHED PERIPHERAL (NORMAL) BLOOD CELLS; PURIFIED DNA AND FFPE FORMATS.

REFERENCE STANDARDS DEVELOPED IN PARTNERSHIP WITH INDUSTRY EXPERTS.

HIGH-QUALITY MANUFACTURED REFERENCE MATERIAL GUARANTEES CONSISTENT GROUND TRUTH.

INTRODUCTION

In immuno-oncology (I-O), the goal is to enable a patient’s immune system to locate and eliminate cancerous cells. Checkpoint inhibitors (CPI), which have recently improved the prognosis for a significant number of cancer patients, work by blocking inhibitory molecules such as PD-L1 and CTLA-4 that may be allowing cancers to evade the adaptive immune system. The US FDA has approved several CPIs such as ipilimumab (Yervoy®, 2011; BMS), pembrolizumab (Keytruda®, 2014; Merck), and nivolumab (Opdivo®, 2014; BMS) primarily for melanoma treatment, but extended to cover treatment of patients with non-small cell lung cancer (NSCLC) and other renal cancers. However, by taking the brakes off the immune system, the use of CPI is associated with a significant risk of developing autoimmune disease.

In order to maximize the safety and efficacy of checkpoint inhibitors, it is beneficial to identify patients who are likely to respond to their use. Since the adaptive immune system can detect changes to proteins, it is thought that the number of somatic mutations that lead to such changes may be correlated with efficacy. The metric of non-silent somatic mutations per megabase of coding DNA has been termed tumor mutational burden (TMB), which has shown some correlation to the efficacy of checkpoint inhibitors. Assessments of TMB are being added to many NGS assays to enable their use for patient selection in I-O clinical trials, and perhaps as companion diagnostics to these therapies. However, it is also known that TMB scores can differ significantly between assays and especially around levels that may be clinical decision points.

To improve and harmonize the measurement of TMB, we have generated and characterized tumor-normal human cell lines (gDNA and FFPEs) by whole exome sequencing (WES) with a range of TMB scores for use in validating targeted NGS panel-based TMB assays, and as controls for TMB measurements in I-O clinical trial projects.

SERASEQ gDNA TMB MIX AND SERASEQ FFPE TMB REFERENCE MATERIALS

Purified gDNA TMB reference materials were made from human lung cancer cell lines and their matched peripheral blood (normal) lymphoblastoid cells derived from the same patients. FFPE TMB reference materials were made from human lung cancer cell lines, blended to 30% tumor content, formalin treated and paraffin embedded into FFPE blocks, then cut into 10µm sections. DNA was extracted, purified and characterized for TMB scores using WES and analyzed by an in-house bioinformatics pipeline in a tumor-normal setting.

TMB Reference Materials	Cancer type	TMB Scores (gDNA)	TMB Scores (FFPE)
Seraseq® TMB Score 7	Small cell lung cancer; carcinoma (stage E)	7.2 ± 0.2	7.2 ± 0.4
Seraseq® TMB Score 9	Lung adenocarcinoma (stage 1)	9.5 ± 0.4	7.5 ± 1.3
Seraseq® TMB Score 20	Non-small cell lung cancer; carcinoma	20.1 ± 0.2	18.6 ± 0.5
Seraseq® TMB Score 26	Lung adenocarcinoma (stage 4)	25.8 ± 0.5	22.8 ± 3.6

ABOUT SERACARE

TRUSTED SUPPLIER
TO THE DIAGNOSTIC
TESTING INDUSTRY
FOR OVER 30 YEARS.

HIGH-QUALITY
CONTROL PRODUCTS,
RAW BIOLOGICAL
MATERIALS AND
IMMUNOASSAY
REAGENTS.

INNOVATIVE TOOLS
AND TECHNOLOGIES
TO PROVIDE
ASSURANCE IN
DIAGNOSTIC ASSAY
PERFORMANCE AND
TEST RESULTS.

FOR MORE
INFORMATION, PLEASE
VISIT OUR WEBSITE:
WWW.SERACARE.COM.



FEATURES AND BENEFITS

- gDNA TMB:
 - 100% tumor-normal matched reference materials
 - Purified DNA in buffer
 - Ready as input into WES or targeted NGS library preparation
- FFPE TMB:
 - 30% tumor FFPE reference standards
 - FFPE sectioned to 10µm per vial
 - Compatible with a range of FFPE extraction kits
- TMB score range of 7 to 26
- Manufactured in GMP-compliant and ISO 13485 certified facilities

ORDERING INFORMATION

Each part code is available for individual purchase.

Product	Format	Material No.	Concentration	Fill Volume	Total Mass
Seraseq® gDNA TMB Mix Score 26	100% tumor-normal matched set - provided in separate vials No extraction required. Purified DNA in buffer.	0710-1323	50 ng/µl / vial 2 vials / kit	10 µl	500 ng / vial
Seraseq® gDNA TMB Mix Score 20		0710-1324	50 ng/µl / vial 2 vials / kit	10 µl	500 ng / vial
Seraseq® gDNA TMB Mix Score 9		0710-1325	50 ng/µl / vial 2 vials / kit	10 µl	500 ng / vial
Seraseq® gDNA TMB Mix Score 7		0710-1326	50 ng/µl / vial 2 vials / kit	10 µl	500 ng / vial
Seraseq® FFPE TMB RM Score 26	30% tumor content Full Process. Extraction Required - FFPE	0710-1307	1 FFPE curl / vial 2 vials / kit	10 µm	>100 ng / curl*
Seraseq® FFPE TMB RM Score 20		0710-1309	1 FFPE curl / vial 2 vials / kit	10 µm	>100 ng / curl*
Seraseq® FFPE TMB RM Score 9		0710-1308	1 FFPE curl / vial 2 vials / kit	10 µm	>100 ng / curl*
Seraseq® FFPE TMB RM Score 7		0710-1310	1 FFPE curl / vial 2 vials / kit	10 µm	>100 ng / curl*

*Based on QIAamp DNA FFPE Tissue Kit and the Qubit dsDNA HS quant. assay

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Seraseq® is a registered trademark SeraCare Life Sciences, Inc.

©2020 SeraCare Life Sciences, Inc. All rights reserved.

MKT-00504-01